Stability and performance of a population pharmacokinetic model

This study aimed to determine the stability (in terms of covariate selection) of a population pharmacokinetic model and evaluate its performance in the absence of a test data set. Data from 88 full-term infants, 11 of whom were human immunodeficiency virus (HIV)-seropositive, taking an antiinfective agent were analyzed using exploratory data analysis methods and the nonlinear mixed-effects modeling (NONMEM) program to obtain the final population pharmacokinetic model. The stability of the population pharmacokinetic model was tested using the nonparametric bootstrap approach in four steps: 1) with the base pharmacokinetic model, 100 bootstrap replicates of the original data were generated by sampling with replacement; 2) ascertainment that each bootstrap data replicate was described by the basic structural model using the NONMEM objective function; 3) generalized additive modeling (GAM) applied to empiric Bayesian estimates for covariate selection at alpha = 0.05 and a frequency (f) cutoff value of 0.50; and 4) NONMEM population model building using covariates selected in the third step with alpha = 0.005. Performance of the population pharmacokinetic model was evaluated using 200 additional bootstrap replicates of the data by fitting the model obtained in step 4 to them. Parameters obtained were compared with those obtained in the model stability step, and improved prediction error, a measure of predictive accuracy as an index of internal validation, was computed. The reciprocal of serum creatinine (RSC; f = 0.73) and HIV (f = 0.70) were selected by GAM as predictors of clearance (Cl). The population pharmacokinetic model obtained without the determination of model stability included RSC as a predictor of Cl, but the final model from the model stability step included both HIV and RSC as predictors of Cl. Final population pharmacokinetic parameters were obtained with this model fitted to the original data; however, the 95% confidence interval on the HIV status regression coefficient included zero, indicating no significance. The mean parameter estimates obtained with the additional 200 bootstrap replicates of data were within 15% of those obtained with the final model at the regression stability step. Bootstrap resampling procedure is useful for evaluating the stability and performance of a population model by repeatedly fitting it to the bootstrap samples when there is no test data set.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Schmidt, S. N. Sabarinath, A. Barbour, D. Abbanat, P. Manitpisitkul, S. Sha, and H. Derendorf Pharmacokinetic-Pharmacodynamic Modeling of the In Vitro Activities of Oxazolidinone Antimicrobial Agents against Methicillin-Resistant Staphylococcus aureus Antimicrob. Agents Chemother., December 1, 2009; 53(12): 5039 - 5045. [Abstract] [Full Text] [PDF]

				S. Abe, K. Chiba, B. Cirincione, T. H. Grasela, K. Ito, and T. Suwa Population Pharmacokinetic Analysis of Linezolid in Patients With Infectious Disease: Application to Lower Body Weight and Elderly Patients J. Clin. Pharmacol., September 1, 2009; 49(9): 1071 - 1078. [Abstract] [Full Text] [PDF]

				L. Zeng, C. E. Nath, E. Y. L. Blair, P. J. Shaw, K. Stephen, J. W. Earl, J. C. Coakley, and A. J. McLachlan Population Pharmacokinetics of Acyclovir in Children and Young People with Malignancy after Administration of Intravenous Acyclovir or Oral Valacyclovir Antimicrob. Agents Chemother., July 1, 2009; 53(7): 2918 - 2927. [Abstract] [Full Text] [PDF]

				K. Wu, N. Goyal, J. G. Stark, and G. Hochhaus Evaluation of the Administration Time Effect on the Cumulative Cortisol Suppression and Cumulative Lymphocytes Suppression for Once-Daily Inhaled Corticosteroids: A Population Modeling/Simulation Approach J. Clin. Pharmacol., September 1, 2008; 48(9): 1069 - 1080. [Abstract] [Full Text] [PDF]

				W. Knebel, M. Palmen, J. A. Dowell, and M. Gastonguay Population Pharmacokinetic Modeling of Epoetin Delta in Pediatric Patients With Chronic Kidney Disease J. Clin. Pharmacol., July 1, 2008; 48(7): 837 - 848. [Abstract] [Full Text] [PDF]

				B. Punyawudho, R. E. Ramsay, F. M. Macias, A. J. Rowan, J. F. Collins, R. C. Brundage, and A. K. Birnbaum Population Pharmacokinetics of Lamotrigine in Elderly Patients J. Clin. Pharmacol., April 1, 2008; 48(4): 455 - 463. [Abstract] [Full Text] [PDF]

				J. T. Mondick, L. Gibiansky, M. R. Gastonguay, J. M. Skolnik, M. Cole, G. J. Veal, A. V. Boddy, P. C. Adamson, and J. S. Barrett Population Pharmacokinetic Investigation of Actinomycin-D in Children and Young Adults J. Clin. Pharmacol., January 1, 2008; 48(1): 35 - 42. [Abstract] [Full Text] [PDF]

				B. G. Charles, A. K. Miller, P. E. Nasveld, M. G. Reid, I. E. Harris, and M. D. Edstein Population Pharmacokinetics of Tafenoquine during Malaria Prophylaxis in Healthy Subjects Antimicrob. Agents Chemother., August 1, 2007; 51(8): 2709 - 2715. [Abstract] [Full Text] [PDF]

				Y. Tanigawara, R. Sato, K. Morita, M. Kaku, N. Aikawa, and K. Shimizu Population Pharmacokinetics of Arbekacin in Patients Infected with Methicillin-Resistant Staphylococcus aureus Antimicrob. Agents Chemother., November 1, 2006; 50(11): 3754 - 3762. [Abstract] [Full Text] [PDF]

				X. Du, C. Li, J. L. Kuti, C. H. Nightingale, and D. P. Nicolau Population Pharmacokinetics and Pharmacodynamics of Meropenem in Pediatric Patients J. Clin. Pharmacol., January 1, 2006; 46(1): 69 - 75. [Abstract] [Full Text] [PDF]

				G. Langdon, J. Wilkins, L. McFadyen, H. McIlleron, P. Smith, and U. S. H. Simonsson Population Pharmacokinetics of Rifapentine and Its Primary Desacetyl Metabolite in South African Tuberculosis Patients Antimicrob. Agents Chemother., November 1, 2005; 49(11): 4429 - 4436. [Abstract] [Full Text] [PDF]

				Y.-N. Sun, J.-F. Lu, A. Joshi, P. Compton, P. Kwon, and R. A. Bruno Population Pharmacokinetics of Efalizumab (Humanized Monoclonal Anti-CD11a Antibody) Following Long-Term Subcutaneous Weekly Dosing in Psoriasis Subjects J. Clin. Pharmacol., April 1, 2005; 45(4): 468 - 476. [Abstract] [Full Text] [PDF]

				E. I Ette, P. J Williams, and J. R Lane Population Pharmacokinetics III: Design, Analysis, and Application of Population Pharmacokinetic Studies Ann. Pharmacother., December 1, 2004; 38(12): 2136 - 2144. [Abstract] [Full Text] [PDF]

				N. Gregoire, V. Gualano, A. Geneteau, L. Millerioux, M. Brault, A. Mignot, and J.-C. Roze Population Pharmacokinetics of Ibuprofen Enantiomers in Very Premature Neonates J. Clin. Pharmacol., October 1, 2004; 44(10): 1114 - 1124. [Abstract] [Full Text] [PDF]

				B Porta-Oltra, J. Perez-Ruixo, M Climente-Marti, M Merino-Sanjuan, D Almenar-Cubells, and N. Jimenez-Torres Population pharmacokinetics of 5-fluorouracil in colorectal cancer patients Journal of Oncology Pharmacy Practice, September 1, 2004; 10(3): 155 - 167. [Abstract] [PDF]

				E. I. Ette, P. J. Williams, Y. H. Kim, J. R. Lane, M.-J. Liu, and E. V. Capparelli Model Appropriateness and Population Pharmacokinetic Modeling J. Clin. Pharmacol., June 1, 2003; 43(6): 610 - 623. [Abstract] [Full Text] [PDF]

				Ch. van Kesteren, R. A.A. Mathot, E. Raymond, J. P. Armand, Ch. Dittrich, H. Dumez, H. Roche, J. P. Droz, C. Punt, M. Ravic, et al. Population Pharmacokinetics of the Novel Anticancer Agent E7070 During Four Phase I Studies: Model Building and Validation J. Clin. Oncol., October 1, 2002; 20(19): 4065 - 4073. [Abstract] [Full Text] [PDF]